Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month BehindRecommendations for Ages 18 Years or Younger, United States, 2022 Show
Using the schedule To make vaccination recommendations, healthcare providers should:
The tables below provide catch-up schedules and minimal intervals between doses for children based on age whose vaccinations have been delayed. Children Age 4 Months through 6 Years
Top of Page Children and Adolescents Age 7 through 18 YearsAdminister recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC. NotesFor vaccination recommendations for persons ages 19 years or older, see the Recommended Adult Immunization Schedule, 2022. Additional information
Dengue Vaccination
For contraindications and precautions to dengue vaccination, see Dengue Appendix Diphtheria, tetanus, and pertussis (DTaP) vaccination
For contraindications and precautions to Diphtheria, tetanus, pertussis (DTaP) vaccination, see DTaP Appendix Haemophilus influenzae type b vaccination
For other catch-up guidance, see Table 2. Vaxelis® can be used for catch-up vaccination in children less than age 5 years. Follow the catch-up schedule even if Vaxelis® is used for one or more doses. For detailed information on use of Vaxelis see www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.
*Unvaccinated = Less than routine series (through age 14 months) OR no doses (age 15 months or older) For contraindications and precautions to Haemophilus influenzae type b (Hib) vaccination, see Hib Appendix Hepatitis A vaccination
For contraindications and precautions to Hepatitis A (HepA) vaccination, see HepA Appendix Hepatitis B vaccination
For detailed revaccination recommendations, see http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html. For contraindications and precautions to Hepatitis B (HepB) vaccination, see HepB Appendix Human papillomavirus vaccination
For contraindications and precautions to Human papillomavirus (HPV) vaccination, see HPV Appendix Influenza vaccination
Measles, mumps, and rubella vaccination
Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
International travel
For contraindications and precautions to Measles, mumps, rubella (MMR), see MMR Appendix Meningococcal serogroup A, C, W, Y vaccination (minimum age: 2 months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])
Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:
Travel in countries with hyperendemic or epidemic meningococcal disease, including countries in the African meningitis belt or during the Hajj
First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military recruits:
Adolescent vaccination of children who received MenACWY prior to age 10 years:
Note: Menactra® should be administered either before or at the same time as DTaP. MenACWY vaccines may be administered simultaneously with MenB vaccines if indicated, but at a different anatomic site, if feasible. For MenACWY booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm. For contraindications and precautions to Meningococcal ACWY (MenACWY) Meningococcal serogroup B vaccination
Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:
Note: Bexsero® and Trumenba® are not interchangeable; the same product should be used for all doses in a series. For MenB booster dose recommendations for groups listed under “Special situations” and in an outbreak setting and additional meningococcal vaccination information, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.
For contraindications and precautions to Meningococcal B (MenB) Pneumococcal vaccination
* Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdf) for complete schedule details. Underlying conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 first. PCV13 and PPSV23 should not be administered during same visit. Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with high-dose, oral corticosteroids); diabetes mellitus: Age 2–5 years
Age 6–18 years
Cerebrospinal fluid leak, cochlear implant: Age 2–5 years
Age 6–18 years
Sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma: Age 2–5 years
Age 6–18 years
Chronic liver disease, alcoholism: Age 6–18 years
*Incomplete series = Not having received all doses in either the recommended series or an age-appropriate catch-up series. See Tables 8, 9, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdf) for complete schedule details. For contraindications and precautions to Pneumococcal conjugate (PCV13), see PCV13 Appendix and Pneumococcal polysaccharide (PPSV23), see PPSV23 Appendix Poliovirus vaccination
Series containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only series:
For contraindications and precautions to Poliovirus vaccine, inactivated (IPV), see Appendix Rotavirus vaccination
For contraindications and precautions to Rotavirus (RV) [RV1 (Rotarix®), RV5 (RotaTeq®)], see Rotavirus Appendix Tetanus,
diphtheria, and pertussis (Tdap) vaccination
*Fully vaccinated = 5 valid doses of DTaP OR 4 valid doses of DTaP if dose 4 was administered at age 4 years or older.
For contraindications and precautions to Tetanus, diphtheria, and acellular pertussis (Tdap) and Tetanus, diphtheria (Td), see Tdap and Td Appendix Varicella vaccination
*Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.
For contraindications and precautions to Varicella (VAR), see VAR Appendix Appendix - Guide to Contraindications and Precautions to Commonly Used VaccinesAdapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions and ACIP’s Recommendations for the Prevention and Control of 2021-22 seasonal influenza with Vaccines. Contraindications1
Precautions2
Vaccine Diphtheria, tetanus, pertussis (DTaP) Tetanus, diphtheria (DT) Contraindications1
Precautions2
Vaccine Haemophilus influenzae type b (Hib) Contraindications1
Precautions2
Vaccine Hepatitis A (HepA) Contraindications1
Precautions2
Vaccine Hepatitis B (HepB) Contraindications1
Precautions2
Vaccine Hepatitis A- Hepatitis B vaccine [HepA-HepB, (Twinrix®)] Contraindications1
Precautions2
Vaccine Human papillomavirus (HPV) Contraindications1
Precautions2
Vaccine Influenza, egg-based, inactivated injectable (IIV4) Contraindications1
Precautions2
Vaccine Influenza, cell culture-based inactivated injectable Contraindications1
Precautions2
Vaccine Influenza, recombinant injectable Contraindications1
Precautions2
Vaccine Influenza, live attenuated [LAIV4, Flumist® Quadrivalent] Contraindications1
Precautions2
Vaccine Measles, mumps, rubella (MMR) Contraindications1
Precautions2
Vaccine Meningococcal ACWY (MenACWY) Contraindications1
Precautions2
Vaccine Meningococcal B (MenB) Contraindications1
Precautions2
Vaccine Pneumococcal conjugate (PCV13) Contraindications1
Precautions2
Vaccine Pneumococcal polysaccharide (PPSV23) Contraindications1
Precautions2
Vaccine Poliovirus vaccine, inactivated (IPV) Contraindications1
Precautions2
Vaccine Rotavirus (RV) [RV1 (Rotarix®), RV5 (RotaTeq®)] Contraindications1
Precautions2
Vaccine Tetanus, diphtheria, and acellular pertussis (Tdap) Tetanus, diphtheria (Td) Contraindications1
Precautions2
Contraindications1
Precautions2
Vaccines in the Child and Adolescent Immunization ScheduleVaccine Diphtheria, tetanus, and acellular pertussis vaccine Trade name(s) Daptacel® Vaccine Diphtheria, tetanus vaccine Trade name(s) No Trade Name Vaccine Haemophilus influenzae type B vaccine Abbreviation(s) Hib (PRP-T) Trade name(s) ActHIB® Vaccine Hepatitis A vaccine Trade name(s) Havrix® Vaccine Hepatitis B vaccine Trade name(s) Engerix-B® Vaccine Human papillomavirus vaccine Trade name(s) Gardasil 9® Vaccine Influenza vaccine (inactivated)
Vaccine Influenza vaccine (live, attenuated) Trade name(s) FluMist® Quadrivalent Vaccine Measles, mumps, and rubella vaccine Vaccine Meningococcal serogroups A, C, W, Y vaccine Abbreviation(s) MenACWY-D Trade name(s) Menactra® Vaccine Meningococcal serogroup B vaccine Abbreviation(s) MenB-4C Trade name(s) Bexsero® Vaccine Pneumococcal 13-valent conjugate vaccine Trade name(s) Prevnar 13® Vaccine Pneumococcal 23-valent polysaccharide vaccine Trade name(s) Pneumovax® 23 Vaccine Poliovirus vaccine (inactivated) Vaccine Rotavirus vaccine Trade name(s) Rotarix® Vaccine Tetanus, diphtheria, and acellular pertussis vaccine Trade name(s) Adacel® Vaccine Tetanus and diphtheria vaccine Trade name(s) Tenivac® Vaccine Varicella vaccine Combination Vaccines(Use combination vaccines instead of separate injections when appropriate) Vaccine DTaP, hepatitis B, and inactivated poliovirus vaccine Abbreviation(s) DTaP-HepB-IPV Vaccine DTaP, inactivated poliovirus, and Haemophilus influenzae type B vaccine Abbreviation(s) DTaP-IPV/Hib Vaccine DTaP and inactivated poliovirus vaccine Trade name(s) Kinrix® Vaccine DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine Abbreviation(s) DTaP-IPV-Hib-HepB Vaccine Measles, mumps, rubella, and varicella vaccines This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics (AAPexternal icon), American Academy of Family Physicians (AAFPexternal icon)), American College of Obstetricians and Gynecologists (ACOGexternal icon), American College of Nurse-Midwives (ACNMexternal icon), American Academy of Physician Associates (AAPAexternal icon), and National Association of Pediatric Nurse Practitioners (NAPNAPexternal icon). The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the February 18, 2022 MMWR. Page last reviewed: February 17, 2022 Which concern would be a priority for the nurse caring for an infant born with exstrophy of the bladder?The primary goal when caring for a child with bladder exstrophy is to: preserve normal kidney function. develop adequate bladder function and promote urinary continence.
Which covering would the nurse use over the exposed area of an infant admitted with exstrophy of the bladder?After delivery, the bladder is covered with a clear plastic dressing to protect it. Children born with bladder exstrophy are treated with reconstructive surgery after birth.
Which child will the nurse identify as at greatest risk for developing a urinary tract infection?Young age – Males younger than one year old and females younger than four years of age are at highest risk. Being uncircumcised – There is a four to 10 times higher risk of UTIs in uncircumcised males.
Which clinical finding suggests developmental dysplasia of the hip in an infant?Early clinical manifestations of developmental dysplasia of the hip (DDH) are identified during examination of the newborn. The classic examination finding is revealed with the Ortolani maneuver, in which a palpable "clunk" is present when the hip is directed in and out of the acetabulum and over the neolimbus.
|